Sacral neuromodulation (SNM) is a guideline-recommended third-line treatment option for managing overactive bladder. Current sacral neuromodulation devices are not rechargeable, and require neurostimulator replacement every 3–6 years. Our study objective was to assess potential cost effects to payers of adopting a rechargeable sacral neurostimulator.
